Recombinant Live-Attenuated Salmonella Vaccine for Veterinary Use

Area of Science:

• Veterinary immunology
• Microbial vaccine development
• Animal health and disease control

Background:

• Vaccination is critical for animal health, emphasizing safety and cost-effectiveness.
• Recombinant live-attenuated Salmonella vaccines (RASVs) utilize balanced lethal systems for stable plasmid vector expression.
• RASVs are suitable for production animals, offering broad-spectrum immunity.

Purpose of the Study:

• To review advancements in RASV technology for veterinary applications.
• To summarize clinical trial data on RASV efficacy and safety.
• To assess the commercial viability of RASVs in animal health.

Main Methods:

• Literature review of RASV development and application.
• Analysis of clinical trial results for efficacy and safety.
• Evaluation of commercialization factors for veterinary vaccines.

Main Results:

• RASVs demonstrate efficacy in providing long-term immunity against diverse pathogens.
• Balanced lethal systems ensure vaccine vector stability post-immunization.
• Clinical trials support the safety and effectiveness of RASVs in production animals.

Conclusions:

• RASVs represent a significant progress in veterinary vaccine technology.
• The efficacy and safety profile of RASVs indicate strong commercial potential.
• RASVs are a promising tool for sustainable animal health management.